KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2025)

Sarepta Therapeutics has reported Operating Leases over the past 7 years, most recently at $199.4 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 3.59% year-over-year to $199.4 million; the TTM value through Dec 2025 reached $199.4 million, up 3.59%, while the annual FY2025 figure was $199.4 million, 3.59% up from the prior year.
  • Operating Leases for Q4 2025 was $199.4 million at Sarepta Therapeutics, down from $215.0 million in the prior quarter.
  • Over five years, Operating Leases peaked at $215.0 million in Q3 2025 and troughed at $35.2 million in Q3 2022.
  • A 5-year average of $117.0 million and a median of $132.0 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: crashed 48.35% in 2021 and later surged 282.5% in 2023.
  • Year by year, Operating Leases stood at $41.5 million in 2021, then skyrocketed by 38.7% to $57.6 million in 2022, then soared by 144.82% to $141.0 million in 2023, then soared by 36.54% to $192.5 million in 2024, then rose by 3.59% to $199.4 million in 2025.
  • Business Quant data shows Operating Leases for SRPT at $199.4 million in Q4 2025, $215.0 million in Q3 2025, and $214.4 million in Q2 2025.